Annexon reports Phase 2 ANX007 data: 0% vision loss in less advanced GA vs 17% sham

Annexon, Inc.

ANX007 monthly-treated patients with less advanced dry AMD lost 0% (0/56) 15+ letters vs 17% (10/59) sham (p=0.0013).
In overall Phase 2 ARCHER, ANX007 monthly reduced 15+ letter loss to 6% (5/89) vs 21% (19/89) sham (p=0.0021).
ANX007 showed 61% decrease in EZ loss in patients with <80% EZ intact at baseline (p=0.0575).
Pivotal Phase 3 ARCHER II data expected in second half 2026.
ANX007 is a first-in-kind Fab targeting C1q intravitreally; data presented at AAO 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.